Recurrent pancreatic cancer treated with N-803 and PD-L1 t-haNK followed by an EGFR-targeted nanocell drug conjugate

Multimodal temporal therapy orchestrated to leverage immunotherapy, tumor-targeted chemotherapy, and natural killer (NK) cell therapy may provide an opportunity to induce immunogenic cell death for tumor response and increased survival in patients with recurrent cancer. The interleukin-15 (IL-15) su...

Full description

Saved in:
Bibliographic Details
Published inThe oncologist (Dayton, Ohio)
Main Authors Moini, Katayoun, Seery, Tara, Nangia, Chaitali, MacDiarmid, Jennifer, Brahmbhatt, Himanshu, Spilman, Patricia, Sender, Lennie, Soon-Shiong, Patrick
Format Journal Article
LanguageEnglish
Published England 04.10.2024
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Multimodal temporal therapy orchestrated to leverage immunotherapy, tumor-targeted chemotherapy, and natural killer (NK) cell therapy may provide an opportunity to induce immunogenic cell death for tumor response and increased survival in patients with recurrent cancer. The interleukin-15 (IL-15) superagonist N-803, an enhancer of NK cells, CD4 + T cells, cytotoxic CD8 + T cells, and memory T-cell activity, combined with off-the-shelf PD-L1-targeted high-affinity NK (PD-L1 t-haNK) cells represent novel immunotherapies designed to overcome an immunosuppressive tumor microenvironment (TME). The epidermal growth factor receptor-targeted antibody-nanocell conjugate E-EDV-D682 provides tumor-targeted chemotherapy in the form of its anthracycline metabolite PNU159682 (nemorubicin) cargo and is currently being studied in combination with immunomodulatory EDVs delivering the adjuvant α-galactosyl ceramide (GC). Here, we report the compassionate use treatment of this combination in a patient with recurrent, metastatic pancreatic cancer (mPC) after 3 lines of therapy. Under the initial single-patient Investigational New Drug (spIND) protocol, the patient received N-803, PD-L1 t-haNK cells, and the albumin doxorubicin conjugate aldoxorubicin for ~27 months. The patient's disease became stable on this regimen, and a transient complete response was observed by ~14 months of therapy. Due to progression, a second spIND protocol was designed whereby the patient received E-EDV-D682 plus EDV-GC for more than 24 months, which resulted in stable disease and the patient's continued survival at the time this report was written. The patient's extended survival despite the dire prognosis associated with recurrent mPC points to the merits of this temporal combination regimen in overcoming immuno-chemo resistance with enhanced immune activity required for tumor response and extended survival.
AbstractList Multimodal temporal therapy orchestrated to leverage immunotherapy, tumor-targeted chemotherapy, and natural killer (NK) cell therapy may provide an opportunity to induce immunogenic cell death for tumor response and increased survival in patients with recurrent cancer. The interleukin-15 (IL-15) superagonist N-803, an enhancer of NK cells, CD4 + T cells, cytotoxic CD8 + T cells, and memory T-cell activity, combined with off-the-shelf PD-L1-targeted high-affinity NK (PD-L1 t-haNK) cells represent novel immunotherapies designed to overcome an immunosuppressive tumor microenvironment (TME). The epidermal growth factor receptor-targeted antibody-nanocell conjugate E-EDV-D682 provides tumor-targeted chemotherapy in the form of its anthracycline metabolite PNU159682 (nemorubicin) cargo and is currently being studied in combination with immunomodulatory EDVs delivering the adjuvant α-galactosyl ceramide (GC). Here, we report the compassionate use treatment of this combination in a patient with recurrent, metastatic pancreatic cancer (mPC) after 3 lines of therapy. Under the initial single-patient Investigational New Drug (spIND) protocol, the patient received N-803, PD-L1 t-haNK cells, and the albumin doxorubicin conjugate aldoxorubicin for ~27 months. The patient's disease became stable on this regimen, and a transient complete response was observed by ~14 months of therapy. Due to progression, a second spIND protocol was designed whereby the patient received E-EDV-D682 plus EDV-GC for more than 24 months, which resulted in stable disease and the patient's continued survival at the time this report was written. The patient's extended survival despite the dire prognosis associated with recurrent mPC points to the merits of this temporal combination regimen in overcoming immuno-chemo resistance with enhanced immune activity required for tumor response and extended survival.
Multimodal temporal therapy orchestrated to leverage immunotherapy, tumor-targeted chemotherapy, and natural killer (NK) cell therapy may provide an opportunity to induce immunogenic cell death for tumor response and increased survival in patients with recurrent cancer. The interleukin-15 (IL-15) superagonist N-803, an enhancer of NK cells, CD4 + T cells, cytotoxic CD8 + T cells, and memory T-cell activity, combined with off-the-shelf PD-L1-targeted high-affinity NK (PD-L1 t-haNK) cells represent novel immunotherapies designed to overcome an immunosuppressive tumor microenvironment (TME). The epidermal growth factor receptor-targeted antibody-nanocell conjugate E-EDV-D682 provides tumor-targeted chemotherapy in the form of its anthracycline metabolite PNU159682 (nemorubicin) cargo and is currently being studied in combination with immunomodulatory EDVs delivering the adjuvant α-galactosyl ceramide (GC). Here, we report the compassionate use treatment of this combination in a patient with recurrent, metastatic pancreatic cancer (mPC) after 3 lines of therapy. Under the initial single-patient Investigational New Drug (spIND) protocol, the patient received N-803, PD-L1 t-haNK cells, and the albumin doxorubicin conjugate aldoxorubicin for ~27 months. The patient's disease became stable on this regimen, and a transient complete response was observed by ~14 months of therapy. Due to progression, a second spIND protocol was designed whereby the patient received E-EDV-D682 plus EDV-GC for more than 24 months, which resulted in stable disease and the patient's continued survival at the time this report was written. The patient's extended survival despite the dire prognosis associated with recurrent mPC points to the merits of this temporal combination regimen in overcoming immuno-chemo resistance with enhanced immune activity required for tumor response and extended survival.Multimodal temporal therapy orchestrated to leverage immunotherapy, tumor-targeted chemotherapy, and natural killer (NK) cell therapy may provide an opportunity to induce immunogenic cell death for tumor response and increased survival in patients with recurrent cancer. The interleukin-15 (IL-15) superagonist N-803, an enhancer of NK cells, CD4 + T cells, cytotoxic CD8 + T cells, and memory T-cell activity, combined with off-the-shelf PD-L1-targeted high-affinity NK (PD-L1 t-haNK) cells represent novel immunotherapies designed to overcome an immunosuppressive tumor microenvironment (TME). The epidermal growth factor receptor-targeted antibody-nanocell conjugate E-EDV-D682 provides tumor-targeted chemotherapy in the form of its anthracycline metabolite PNU159682 (nemorubicin) cargo and is currently being studied in combination with immunomodulatory EDVs delivering the adjuvant α-galactosyl ceramide (GC). Here, we report the compassionate use treatment of this combination in a patient with recurrent, metastatic pancreatic cancer (mPC) after 3 lines of therapy. Under the initial single-patient Investigational New Drug (spIND) protocol, the patient received N-803, PD-L1 t-haNK cells, and the albumin doxorubicin conjugate aldoxorubicin for ~27 months. The patient's disease became stable on this regimen, and a transient complete response was observed by ~14 months of therapy. Due to progression, a second spIND protocol was designed whereby the patient received E-EDV-D682 plus EDV-GC for more than 24 months, which resulted in stable disease and the patient's continued survival at the time this report was written. The patient's extended survival despite the dire prognosis associated with recurrent mPC points to the merits of this temporal combination regimen in overcoming immuno-chemo resistance with enhanced immune activity required for tumor response and extended survival.
Author Moini, Katayoun
Brahmbhatt, Himanshu
MacDiarmid, Jennifer
Sender, Lennie
Nangia, Chaitali
Spilman, Patricia
Seery, Tara
Soon-Shiong, Patrick
Author_xml – sequence: 1
  givenname: Katayoun
  surname: Moini
  fullname: Moini, Katayoun
  organization: Chan Soon-Shiong Institute for Medicine (CSSIFM), El Segundo, CA 90245, United States
– sequence: 2
  givenname: Tara
  surname: Seery
  fullname: Seery, Tara
  organization: Chan Soon-Shiong Institute for Medicine (CSSIFM), El Segundo, CA 90245, United States
– sequence: 3
  givenname: Chaitali
  surname: Nangia
  fullname: Nangia, Chaitali
  organization: Chan Soon-Shiong Institute for Medicine (CSSIFM), El Segundo, CA 90245, United States
– sequence: 4
  givenname: Jennifer
  surname: MacDiarmid
  fullname: MacDiarmid, Jennifer
  organization: EnGeneIC, Ltd., North Ryde, Sydney, NSW 2113, Australia
– sequence: 5
  givenname: Himanshu
  surname: Brahmbhatt
  fullname: Brahmbhatt, Himanshu
  organization: EnGeneIC, Ltd., North Ryde, Sydney, NSW 2113, Australia
– sequence: 6
  givenname: Patricia
  orcidid: 0000-0003-2626-6475
  surname: Spilman
  fullname: Spilman, Patricia
  organization: ImmunityBio, Inc., Culver City, CA 90232, United States
– sequence: 7
  givenname: Lennie
  surname: Sender
  fullname: Sender, Lennie
  organization: ImmunityBio, Inc., Culver City, CA 90232, United States
– sequence: 8
  givenname: Patrick
  surname: Soon-Shiong
  fullname: Soon-Shiong, Patrick
  organization: ImmunityBio, Inc., Culver City, CA 90232, United States
BackLink https://www.ncbi.nlm.nih.gov/pubmed/39373598$$D View this record in MEDLINE/PubMed
BookMark eNo9kM1LAzEQxYMo1q-rR8nRSzTJbNzNUbRVsVQpCt6WbHZSW7ZJzWYp_e_d0upp3jC_9xjeKTn0wSMhl4LfCK7hNngbmnAbNgblXX5AToTKNMs0_zrsNS-A5ULpATlt2wXnvQR5TAagIQelixOSpmi7GNEnujLeRjRpbqntJUaativWdD1P33TCCg7U-Jq-P7KxoIl9m8krdaFpwrqHqk1_pMOn0ZQlE2e4NXrjg8WmoXXsZtQGv-hmfeI5OXKmafFiP8_I52j48fDMxm9PLw_3Y2al5IkJA6hBa2etE0rllTYATioHWSFFBtKhwJqLKoc7q5ys60xJCdw4USnIFJyR613uKoafDttULuft9h_jMXRtCUJArkDnRY_e7FAbQ9tGdOUqzpcmbkrBy23T5a7pct90b7jaZ3fVEut__K9a-AW1Pn0h
Cites_doi 10.1016/S1470-2045(19)30795-8
10.1016/j.ccr.2007.03.012
10.6004/jnccn.2021.0017
10.1136/jitc-2019-000450
10.18632/oncotarget.5181
10.1016/j.ctrv.2020.102016
10.1200/JCO.2017.35.4_suppl.TPS510
10.2147/DDDT.S140638
10.1016/j.bmcl.2020.127640
10.1016/j.ygyno.2017.02.028
10.1038/s43856-023-00243-7
10.12688/f1000research.21981.1
10.1136/jitc-2020-001098
10.3389/fonc.2022.862600
10.1080/2162402X.2021.1912885
10.1002/jcph.304
10.32607/actanaturae.11523
10.1016/j.lpm.2019.02.025
10.1016/S1470-2045(16)00172-8
10.1016/j.ccell.2020.02.001
10.1158/1078-0432.CCR-23-1821
10.1016/j.copbio.2011.04.008
10.1007/s12029-015-9724-1
10.1200/JCO.2023.41.4_suppl.711
10.3390/jcm11175084
10.1136/jitc-2020-002128
10.1200/JCO.2022.40.16_suppl.4147
10.1016/S1470-2045(18)30148-7
10.1158/1078-0432.CCR-18-0945
10.1200/JCO.2020.38.15_suppl.e15015
10.18632/oncotarget.7470
10.1016/j.ccell.2020.08.004
10.1634/theoncologist.2019-0608
10.1200/JCO.2020.38.15_suppl.4632
ContentType Journal Article
Copyright The Author(s) 2024. Published by Oxford University Press.
Copyright_xml – notice: The Author(s) 2024. Published by Oxford University Press.
DBID NPM
AAYXX
CITATION
7X8
DOI 10.1093/oncolo/oyae267
DatabaseName PubMed
CrossRef
MEDLINE - Academic
DatabaseTitle PubMed
CrossRef
MEDLINE - Academic
DatabaseTitleList PubMed
CrossRef
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1549-490X
ExternalDocumentID 10_1093_oncolo_oyae267
39373598
Genre Journal Article
GrantInformation_xml – fundername: ImmunityBio, Inc
– fundername: EnGeneIC, Ltd
GroupedDBID ---
0R~
123
18M
1OC
24P
36B
4.4
AAPXW
AAVAP
AAWTL
AAZKR
ABEJV
ABPTD
ABXVV
ADBBV
ADXAS
AEGXH
AENEX
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
CS3
DCZOG
DIK
DU5
E3Z
EBD
EBS
EMB
EMOBN
F5P
FRP
GROUPED_DOAJ
GX1
HYE
HZ~
IAO
IHR
INH
ITC
LUTES
LYRES
NPM
O9-
OK1
P2P
P2W
RAO
RHF
RHI
ROX
RPM
SV3
TOX
TR2
W2D
WIN
WOHZO
WOQ
XSB
ZZTAW
AAYXX
CITATION
7X8
ID FETCH-LOGICAL-c220t-1a3e9399fccf1557b9a33f25f34821432fe1ed01b736c5f2dd452230af1b53453
ISSN 1083-7159
1549-490X
IngestDate Thu Dec 05 20:45:52 EST 2024
Fri Dec 06 07:38:02 EST 2024
Sat Nov 02 12:28:33 EDT 2024
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords PD-L1 t-haNK
EDV-α-galactosyl ceramide
E-EDV-D682
N-803
metastatic pancreatic cancer
Language English
License The Author(s) 2024. Published by Oxford University Press.
https://creativecommons.org/licenses/by/4.0
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c220t-1a3e9399fccf1557b9a33f25f34821432fe1ed01b736c5f2dd452230af1b53453
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0003-2626-6475
OpenAccessLink https://academic.oup.com/oncolo/advance-article-pdf/doi/10.1093/oncolo/oyae267/59622144/oyae267.pdf
PMID 39373598
PQID 3113753978
PQPubID 23479
ParticipantIDs proquest_miscellaneous_3113753978
crossref_primary_10_1093_oncolo_oyae267
pubmed_primary_39373598
PublicationCentury 2000
PublicationDate 2024-Oct-04
2024-10-04
20241004
PublicationDateYYYYMMDD 2024-10-04
PublicationDate_xml – month: 10
  year: 2024
  text: 2024-Oct-04
  day: 04
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle The oncologist (Dayton, Ohio)
PublicationTitleAlternate Oncologist
PublicationYear 2024
References Gatti-Mays (2024100713283518900_CIT0020) 2019; 25
Kistler (2024100713283518900_CIT0027) 2018
Drusbosky (2024100713283518900_CIT0026) 2020; 8
Kim (2024100713283518900_CIT0039) 2016; 7
Miki (2024100713283518900_CIT0004) 2022; 11
Seery (2024100713283518900_CIT0023)
Tomlins (2024100713283518900_CIT0034) 2023; 3
Gabitzsch (2024100713283518900_CIT0021) 2015; 6
Tempero (2024100713283518900_CIT0002) 2021; 19
Chen (2024100713283518900_CIT0036) 2014; 54
FDA (2024100713283518900_CIT0016) 2024
Seery (2024100713283518900_CIT0025) 2022; 40
Fabian (2024100713283518900_CIT0017) 2020; 8
Seery (2024100713283518900_CIT0022) 2019; 37
Felices (2024100713283518900_CIT0038) 2017; 145
Christenson (2024100713283518900_CIT0008) 2020; 21
Sagnella (2024100713283518900_CIT0032) 2020; 37
Troitskaya (2024100713283518900_CIT0035) 2022; 14
MacDiarmid (2024100713283518900_CIT0030) 2011; 22
Springfeld (2024100713283518900_CIT0037) 2019; 48
Bear (2024100713283518900_CIT0007) 2020; 38
Lundy (2024100713283518900_CIT0029) 2020; 38
Gong (2024100713283518900_CIT0019) 2018; 12
Kim (2024100713283518900_CIT0005) 2023; 41
Carrato (2024100713283518900_CIT0001) 2015; 46
Suker (2024100713283518900_CIT0003) 2016; 17
Holte (2024100713283518900_CIT0028) 2020; 30
Ganju (2024100713283518900_CIT0033) 2024; 30
Luo (2024100713283518900_CIT0006) 2022; 12
Margolin (2024100713283518900_CIT0013) 2018; 24
Lee (2024100713283518900_CIT0018) 2021; 9
Seery (2024100713283518900_CIT0024) 2020; 38
MacDiarmid (2024100713283518900_CIT0031) 2007; 11
Roth (2024100713283518900_CIT0009) 2020; 9
Schizas (2024100713283518900_CIT0010) 2020; 86
Acoba (2024100713283518900_CIT0012) 2017; 35
Wrangle (2024100713283518900_CIT0011) 2018; 19
Chamie (2024100713283518900_CIT0015) 2022; 2
Rosser (2024100713283518900_CIT0014) 2021; 10
References_xml – volume: 21
  start-page: e135
  year: 2020
  ident: 2024100713283518900_CIT0008
  article-title: Current and emerging therapies for patients with advanced pancreatic ductal adenocarcinoma: a bright future
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(19)30795-8
  contributor:
    fullname: Christenson
– volume: 11
  start-page: 431
  year: 2007
  ident: 2024100713283518900_CIT0031
  article-title: Bacterially derived 400 nm particles for encapsulation and cancer cell targeting of chemotherapeutics
  publication-title: Cancer Cell
  doi: 10.1016/j.ccr.2007.03.012
  contributor:
    fullname: MacDiarmid
– volume: 19
  start-page: 439
  year: 2021
  ident: 2024100713283518900_CIT0002
  article-title: Pancreatic adenocarcinoma, version 2.2021, NCCN Clinical Practice Guidelines in Oncology
  publication-title: J Natl Compr Canc Netw
  doi: 10.6004/jnccn.2021.0017
  contributor:
    fullname: Tempero
– volume: 8
  start-page: e000450
  year: 2020
  ident: 2024100713283518900_CIT0017
  article-title: PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations
  publication-title: J ImmunoTher Cancer
  doi: 10.1136/jitc-2019-000450
  contributor:
    fullname: Fabian
– volume: 6
  start-page: 31344
  year: 2015
  ident: 2024100713283518900_CIT0021
  article-title: The generation and analyses of a novel combination of recombinant adenovirus vaccines targeting three tumor antigens as an immunotherapeutic
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.5181
  contributor:
    fullname: Gabitzsch
– volume: 86
  start-page: 102016
  year: 2020
  ident: 2024100713283518900_CIT0010
  article-title: Immunotherapy for pancreatic cancer: a 2020 update
  publication-title: Cancer Treat Rev
  doi: 10.1016/j.ctrv.2020.102016
  contributor:
    fullname: Schizas
– ident: 2024100713283518900_CIT0023
  article-title: QUILT-88: NANT pancreatic cancer vaccine in 3rd, 4th, and 5th line advanced disease
  contributor:
    fullname: Seery
– volume: 35
  start-page: TPS510
  year: 2017
  ident: 2024100713283518900_CIT0012
  article-title: Phase Ib/II study of ALT-803 in combination with gemcitabine and nab-paclitaxel in patients with advanced pancreatic cancer
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2017.35.4_suppl.TPS510
  contributor:
    fullname: Acoba
– volume: 12
  start-page: 777
  year: 2018
  ident: 2024100713283518900_CIT0019
  article-title: Aldoxorubicin: a tumor-targeted doxorubicin conjugate for relapsed or refractory soft tissue sarcomas
  publication-title: Drug Des Devel Ther
  doi: 10.2147/DDDT.S140638
  contributor:
    fullname: Gong
– volume: 30
  start-page: 127640
  year: 2020
  ident: 2024100713283518900_CIT0028
  article-title: Evaluation of PNU-159682 antibody drug conjugates (ADCs)
  publication-title: Bioorg Med Chem Lett
  doi: 10.1016/j.bmcl.2020.127640
  contributor:
    fullname: Holte
– volume: 145
  start-page: 453
  year: 2017
  ident: 2024100713283518900_CIT0038
  article-title: IL-15 super-agonist (ALT-803) enhances natural killer (NK) cell function against ovarian cancer
  publication-title: Gynecol Oncol
  doi: 10.1016/j.ygyno.2017.02.028
  contributor:
    fullname: Felices
– volume: 3
  start-page: 14
  year: 2023
  ident: 2024100713283518900_CIT0034
  article-title: Development and validation of an integrative pan-solid tumor predictor of PD-1/PD-L1 blockade benefit
  publication-title: Commun Med
  doi: 10.1038/s43856-023-00243-7
  contributor:
    fullname: Tomlins
– volume: 9
  start-page: F1000 Faculty Rev-131
  year: 2020
  ident: 2024100713283518900_CIT0009
  article-title: Recent advances in the treatment of pancreatic cancer
  publication-title: F1000Res
  doi: 10.12688/f1000research.21981.1
  contributor:
    fullname: Roth
– volume: 8
  start-page: e001098
  year: 2020
  ident: 2024100713283518900_CIT0026
  article-title: Complete response to avelumab and IL-15 superagonist N-803 with Abraxane in Merkel cell carcinoma: a case study
  publication-title: J ImmunoTher Cancer
  doi: 10.1136/jitc-2020-001098
  contributor:
    fullname: Drusbosky
– volume: 12
  start-page: 862600
  year: 2022
  ident: 2024100713283518900_CIT0006
  article-title: Case report: a case of locally advanced pancreatic cancer which achieved progression free for over 12 months by subsequent therapy with anlotinib hydrochloride plus tegafur-gimeracil-oteracil potassium (TS-1)
  publication-title: Front Oncol
  doi: 10.3389/fonc.2022.862600
  contributor:
    fullname: Luo
– volume: 10
  start-page: 1
  year: 2021
  ident: 2024100713283518900_CIT0014
  article-title: Safety, tolerability, and long-term clinical outcomes of an IL-15 analogue (N-803) admixed with bacillus calmette-guérin (BCG) for the treatment of bladder cancer
  publication-title: Oncoimmunology
  doi: 10.1080/2162402X.2021.1912885
  contributor:
    fullname: Rosser
– volume: 54
  start-page: 1097
  year: 2014
  ident: 2024100713283518900_CIT0036
  article-title: Pharmacokinetics and pharmacodynamics of nab-paclitaxel in patients with solid tumors: disposition kinetics and pharmacology distinct from solvent-based paclitaxel
  publication-title: J Clin Pharmacol
  doi: 10.1002/jcph.304
  contributor:
    fullname: Chen
– volume: 14
  start-page: 40
  year: 2022
  ident: 2024100713283518900_CIT0035
  article-title: Immunogenic cell death in cancer therapy
  publication-title: Acta Naturae
  doi: 10.32607/actanaturae.11523
  contributor:
    fullname: Troitskaya
– volume: 48
  start-page: e159
  year: 2019
  ident: 2024100713283518900_CIT0037
  article-title: Chemotherapy for pancreatic cancer
  publication-title: Presse Med
  doi: 10.1016/j.lpm.2019.02.025
  contributor:
    fullname: Springfeld
– volume: 17
  start-page: 801
  year: 2016
  ident: 2024100713283518900_CIT0003
  article-title: FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(16)00172-8
  contributor:
    fullname: Suker
– volume: 37
  start-page: 354
  year: 2020
  ident: 2024100713283518900_CIT0032
  article-title: Cyto-immuno-therapy for cancer: a pathway elicited by tumor-targeted, cytotoxic drug-packaged bacterially derived nanocells
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2020.02.001
  contributor:
    fullname: Sagnella
– year: 2024
  ident: 2024100713283518900_CIT0016
  article-title: FDA approves nogapendekin alfa inbakicept-pmln for BCG-unresponsive non-muscle invasive bladder cancer
  publication-title: US Food and Drug Administration
  contributor:
    fullname: FDA
– volume: 37
  start-page: TPS4
  year: 2019
  ident: 2024100713283518900_CIT0022
  article-title: NANT cancer vaccine an orchestration of immunogenic cell death by overcoming immune suppression and activating NK and T cell therapy in patients with third line or greater metastatic pancreatic cancer
  publication-title: J Clin Oncol
  contributor:
    fullname: Seery
– volume: 30
  start-page: 304
  year: 2024
  ident: 2024100713283518900_CIT0033
  article-title: Phase I/IIa trial in advanced pancreatic ductal adenocarcinoma treated with cytotoxic drug-packaged, EGFR-targeted nanocells and glycolipid-packaged nanocells
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-23-1821
  contributor:
    fullname: Ganju
– volume: 22
  start-page: 909
  year: 2011
  ident: 2024100713283518900_CIT0030
  article-title: Minicells: versatile vectors for targeted drug or si/shRNA cancer therapy
  publication-title: Curr Opin Biotechnol
  doi: 10.1016/j.copbio.2011.04.008
  contributor:
    fullname: MacDiarmid
– volume: 46
  start-page: 201
  year: 2015
  ident: 2024100713283518900_CIT0001
  article-title: A systematic review of the burden of pancreatic cancer in Europe: real-world impact on survival, quality of life and costs
  publication-title: J Gastrointest Cancer
  doi: 10.1007/s12029-015-9724-1
  contributor:
    fullname: Carrato
– volume: 41
  start-page: 711
  year: 2023
  ident: 2024100713283518900_CIT0005
  article-title: Efficacy of the third-line chemotherapy in patients with advanced pancreatic cancer
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2023.41.4_suppl.711
  contributor:
    fullname: Kim
– volume: 11
  start-page: 5084
  year: 2022
  ident: 2024100713283518900_CIT0004
  article-title: Treatment effect and safety of nanoliposomal irinotecan with fluorouracil and folinic acid after gemcitabine-based therapy in patients with advanced pancreatic cancer: a multicenter, prospective observational study
  publication-title: J Clin Med
  doi: 10.3390/jcm11175084
  contributor:
    fullname: Miki
– volume: 9
  start-page: e002128
  year: 2021
  ident: 2024100713283518900_CIT0018
  article-title: Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cells
  publication-title: J ImmunoTher Cancer
  doi: 10.1136/jitc-2020-002128
  contributor:
    fullname: Lee
– volume: 40
  start-page: 4147
  year: 2022
  ident: 2024100713283518900_CIT0025
  article-title: Phase 2 Quilt 88 trial of DAMP inducers combined with IL15 superagonist, N-803, and anti–PD-L1 NK cell therapy more than doubles historical overall survival in patients with third- to sixth-line advanced pancreatic cancer
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2022.40.16_suppl.4147
  contributor:
    fullname: Seery
– volume: 19
  start-page: 694
  year: 2018
  ident: 2024100713283518900_CIT0011
  article-title: ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(18)30148-7
  contributor:
    fullname: Wrangle
– volume: 24
  start-page: 5552
  year: 2018
  ident: 2024100713283518900_CIT0013
  article-title: Phase I trial of ALT-803, a novel recombinant IL15 complex, in patients with advanced solid tumors
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-18-0945
  contributor:
    fullname: Margolin
– volume: 38
  start-page: e15015
  year: 2020
  ident: 2024100713283518900_CIT0024
  article-title: Immunotherapy combining NK and T cell activation with IL-15 super agonist (N-803), off-the-shelf high-affinity CD16 NK (haNK) or PDL1 targeted haNK and checkpoint inhibitor in relapsed/refractory advanced pancreatic cancer
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2020.38.15_suppl.e15015
  contributor:
    fullname: Seery
– volume: 7
  start-page: 16130
  year: 2016
  ident: 2024100713283518900_CIT0039
  article-title: IL-15 superagonist/IL-15RαSushi-Fc fusion complex (IL-15SA/IL-15RαSu-Fc; ALT-803) markedly enhances specific subpopulations of NK and memory CD8+ T cells, and mediates potent anti-tumor activity against murine breast and colon carcinomas
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.7470
  contributor:
    fullname: Kim
– volume: 38
  start-page: 788
  year: 2020
  ident: 2024100713283518900_CIT0007
  article-title: Challenges and opportunities for pancreatic cancer immunotherapy
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2020.08.004
  contributor:
    fullname: Bear
– start-page: P310
  year: 2018
  ident: 2024100713283518900_CIT0027
  article-title: NANT Cancer Vaccine an orchestration of immunogenic cell death by overcoming immune suppression and activating NK and T cell therapy in patients with third line or greater TNBC and head & neck SCC
  contributor:
    fullname: Kistler
– volume: 2
  start-page: 1
  year: 2022
  ident: 2024100713283518900_CIT0015
  article-title: IL-15 superagonist NAI in BCG-unresponsive non–muscle-invasive bladder cancer
  publication-title: NEJM Evidence
  contributor:
    fullname: Chamie
– volume: 25
  start-page: 479
  year: 2019
  ident: 2024100713283518900_CIT0020
  article-title: A phase I trial using a multitargeted recombinant adenovirus 5 (CEA/MUC1/Brachyury)-based immunotherapy vaccine regimen in patients with advanced cancer
  publication-title: Oncologist
  doi: 10.1634/theoncologist.2019-0608
  contributor:
    fullname: Gatti-Mays
– volume: 38
  start-page: 4632
  year: 2020
  ident: 2024100713283518900_CIT0029
  article-title: Interim data: Phase I/IIa study of EGFR-targeted EDV nanocells carrying cytotoxic drug PNU-159682 (E-EDV-D682) with immunomodulatory adjuvant EDVs carrying α-galactosyl ceramide (EDV-GC) in patients with recurrent, metastatic pancreatic cancer
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2020.38.15_suppl.4632
  contributor:
    fullname: Lundy
SSID ssj0015932
Score 2.4923363
Snippet Multimodal temporal therapy orchestrated to leverage immunotherapy, tumor-targeted chemotherapy, and natural killer (NK) cell therapy may provide an...
SourceID proquest
crossref
pubmed
SourceType Aggregation Database
Index Database
Title Recurrent pancreatic cancer treated with N-803 and PD-L1 t-haNK followed by an EGFR-targeted nanocell drug conjugate
URI https://www.ncbi.nlm.nih.gov/pubmed/39373598
https://www.proquest.com/docview/3113753978
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1da9swFBVbB6UvY99LtxUNBnsIXm3LH_XjaJqVbUmhpJA3I9vS4j3YJXUY2a_fvbqy4kIL216MsbCNdY-ko-ujI8Y-lGmkS1-lXhZp4UVpGHsyQbGDTqR_oqIiMpZCs3lyfhV9XcbLnWzMrC7pik_l7zvXlfxPVOEaxBVXyf5DZN1D4QKcQ3zhCBGG41_F-BKT5cZeCdo00b8SZVylWpOCvNeWz2GIELQwYOJ9D8adt5Lzb2MNIGh_EQeFdn72ZXrpkTQcRQGyaTGtP67WG1yX2_zcYMptyGYRY21jfK8BLUhWJ3Jr9fgXq7odpBlmbd3UVr4ht9DFuNSOUvQnfyHXboiAPv8HqXhPVxK3NakHmfNJLQGd1VCbM8xdhJFRwVH-QNn-NsJN7vzlnb05OV3Rd-DJVqqQNu8YBPfavHGKxn7oRrgb15zasC96yB6hXSLusLC4WLp_TTFQWGfnKY7pdcf2ZQdsv7_9NnO5ZzpiaMniCXts5xP8M4HjKXugmmdsf2YVE89Z5zDCdxjhhBFuMcIRI9xghANGuMEIJ4zwHiO82EIhv4UR3mOEI0a4w8gLdjU9W5yee3anDa8MQ7_zAilUBlRVl6UGgpkWmRRCh7FG6yNg1KFWgar8oEhFUsY6rCo04he-1EERiygWL9le0zbqNeNplRRAcqGpAxWvhCqA36dppiVEGhVKI_axr8X8mgxVchJCiJyqPrdVP2Lv-0rOoc_Dr5GNajc3uQgCAdPsLD0ZsVdU--5ZfbQO7y15ww52WHzL9rr1Rr0DZtkVRyYjc2Tg8QcBvntq
link.rule.ids 314,780,784,864,27924,27925
linkProvider Oxford University Press
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Recurrent+pancreatic+cancer+treated+with+N-803+and+PD-L1+t-haNK+followed+by+an+EGFR-targeted+nanocell+drug+conjugate&rft.jtitle=The+oncologist+%28Dayton%2C+Ohio%29&rft.au=Moini%2C+Katayoun&rft.au=Seery%2C+Tara&rft.au=Nangia%2C+Chaitali&rft.au=MacDiarmid%2C+Jennifer&rft.date=2024-10-04&rft.eissn=1549-490X&rft_id=info:doi/10.1093%2Foncolo%2Foyae267&rft_id=info%3Apmid%2F39373598&rft.externalDocID=39373598
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1083-7159&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1083-7159&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1083-7159&client=summon